

1 Dalmore Drive,  
Scoresby,  
Victoria 3179  
AUSTRALIA  
T: +61 (0)3 9763-1287  
F: +61 (0)3 9763-2817  
[www.generabiosystems.com](http://www.generabiosystems.com)

**Wednesday 31 July 2019**

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)  
APPENDIX 4C QUARTERLY CASH FLOW AND BUSINESS UPDATE**

---

Genera Biosystems Limited (ASX:GBI) ('Genera' or 'the Company') is pleased to provide its quarterly cash flow report and a business update.

In its March quarter update Genera flagged that it intended to undertake a capital raise of (up to) \$3.575 million via a placement of Ordinary Shares of Genera at an Issue Price of \$0.13 per share ("Capital Raise"). Proceeds of the placement were to be applied largely to redeem existing Convertible Notes while the Company intended to retain sufficient funds from the Capital Raise to fund ongoing general working capital requirements.

Subsequent to this announcement the Board of Genera formed the view that there was insufficient investor demand to meet the required minimum raise amount which was required to be met if Genera were to proceed with the issuance of Ordinary Shares. Engagement was held with existing Series B Noteholders and it was determined that the optimal path is instead to pursue a 2-step funding path.

This path shall involve a smaller tranching capital raise of up to \$2.0 million via the issuance of new Series B Convertible Notes at an Issue price of \$225.00 per Note. These funds shall be raised on a required basis between the month of June and early September and shall be applied to fund ongoing general working capital requirements, including but not limited to the preparation for a significant clinical study for Genera's PapType® HPV assay, the launch of the new sexually transmitted infections panel and other corporate partnering objectives, namely focussed upon the North American market.

Genera retains the view that the market opportunity for PapType® is best addressed via a centralised US Lab with complementary market expertise and OB/GYN reach.

The Board of Genera currently intends to undertake a more substantial Ordinary Share capital raise to redeem a significant proportion of 2014/2015 issued Notes in a late September/October timeframe. Based upon discussions held to date with selected existing Noteholders as well as those subscribing for newly issued June to September 2019 Notes, the Board of Genera envisages that these Notes, alongside a material amount of earlier vintage Notes, will most likely be converted to Ordinary Shares contemporaneous to more substantive Ordinary Share capital raise.

Genera's goal remains to finish the 2019 calendar year with a clean balance sheet and stable capital structure with sufficient liquidity and working capital to fund the numerous commercial opportunities before it.

Genera's shares shall remain suspended from trading on ASX until the proposed restructure is complete.

Genera intends to work with its auditors to complete and lodge its half year and full year accounts with ASX as soon as practical and in any event will lodge the half year and full year accounts prior to the proposed more substantive Ordinary Share capital raise.

The Board thanks its long standing, loyal shareholders' patience while it delivers on its objectives in a manner that delivers optimal value for all stakeholders.

For further information please contact:

Mr Richard Hannebery  
Chief Executive Officer  
Genera Biosystems Limited  
Telephone: +61 (0)3 9763 1287  
[www.generabiosystems.com.au](http://www.generabiosystems.com.au)

**About Genera Biosystems** : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.<sup>1</sup>

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

PapType®, an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType®, Genera has also commercialized and gained ARTG listing and CE mark for RTIplex™, a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera’s development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 2<sup>nd</sup> half of 2019, with plans to broaden the AmpaSand® test menu further to 5 to 6 highly competitive single-well multiplex MDx assays by close of 2020.

PapType®, RTIplex™, and the tests in development, employ the AmpaSand® biochemistry as well as Genera’s proprietary ARTG listed and CE-IVD marked QPlots™ automated analytical and reporting software that is compatible with most Laboratory Information Management Systems (‘LIMS’).

All the components of the Genera MDx system, including AmpaSand® and QPlots™, have been optimized to run on Beckman Coulter’s innovative CytoFLEX™ flow cytometry system.

---

<sup>1</sup> All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Genera Biosystems Limited

**ABN**

69 098 663 837

**Quarter ended ("current quarter")**

30 June 2019

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	116
1.2 Payments for		
(a) research and development	(10)	(159)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(223)	(965)
(f) administration and corporate costs	(59)	(385)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives (R&D)	-	438
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(292)</b>	<b>(955)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
(d) intellectual property	-	(74)
(e) other non-current assets	-	(243)
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>(317)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	255	1378
3.6 Repayment of borrowings	-	(171)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
<b>3.10 Net cash from / (used in) financing activities</b>	<b>255</b>	<b>1207</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	50	78
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(292)	(955)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	(317)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	255	1207

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	-	-
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>13</b>	<b>13</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	13	50
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>13</b>	<b>50</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter \$A'000</b>
22
-

Payment of director salaries and directors' fees for the quarter.

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

<b>Current quarter \$A'000</b>
-
-

-

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	2,500	2,338
8.2 Credit standby arrangements	-	-
8.3 Convertible notes	5,000	3,075
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Loan facilities include Mezzanine loans and other short term non-interest-bearing loans.

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	250
9.2 Product manufacturing and operating costs	150
9.3 Advertising and marketing	50
9.4 Leased assets	50
9.5 Staff costs	450
9.6 Administration and corporate costs	150
9.7 Other (Debt repayment)	20
<b>9.8 Total estimated cash outflows</b>	<b>1,120</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:

.....  
(Executive Director)

Date: 31 July 2019

Print name: Richard Hannebery

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.